PARP12

Across TCGA pan-cancer cohorts, PARP12 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated PARP12 data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher PARP12 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PARP12 expression acts as an unfavorable survival marker.

BRCA, KIRC, and TGCT are the cancer types where PARP12 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.087	0.924	<.001	24	view →
KIRC	OS	Median	II,III,IV	0.172	0.696	.030	12	view →
TGCT	DFS	Median	All	0.082	0.837	<.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
BLCA	OS	Median	IV	0.018	0.600	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
STAD	DFS	Median	All	0.264	0.713	.009	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

PARP12–BRCA (OS)

Open the BRCA breakdown →